Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07024992 · ClinicalTrials.gov registry record · Phase 2
Enhancing Smoking Cessation for African American People Everywhere
A Phase 2 study, sponsored by University of Houston.
- Not yet
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT07024992: Clinical Trial Phase 2 study, sponsored by University of Houston.
NCT07024992 is a Phase 2 study that has not yet begun recruiting, run by University of Houston. The registered enrollment target is 300 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07024992, a Phase 2 study, has not yet begun recruiting, sponsored by University of Houston.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
The present study aims to investigate the efficacy of an mHealth smoking cessation and HIV disease management intervention among a nationally representative sample of African America/Black (hereafter refer to as Black) persons with HIV/AIDS (PWH) who smoke cigarettes. Participants will be randomized into one of three conditions: (1) the intervention, ESCAPE (Enhancing Smoking Cessation for African American People Everywhere) + Nicotine Replacement Medications (NRT), (2) the National Cancer Institute's (NCI) quitSTART app, the standard mobile smoking cessation treatment + NRT, and (3) an assessment-only control group + NRT.
Primary Outcome
PPA will be defined as no cigarette smoking within the past 7 days, and will be biochemically verified via assessment of expired carbon monoxide (\< 6 ppm).
Interventions
- BEHAVIORAL ESCAPE app + NRT
- BEHAVIORAL quiSTART app + NRT
- BEHAVIORAL Control (CTRL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 2 |
What is known before NCT07024992 opens enrollment
NCT07024992 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher).
The record links to 0 conditions, and to 3 interventions - of which ESCAPE app + NRT is the first listed.
NCT07024992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07024992 about?
NCT07024992 is a clinical study titled "Enhancing Smoking Cessation for African American People Everywhere". The present study aims to investigate the efficacy of an mHealth smoking cessation and HIV disease management intervention among a nationally representative sample of African America/Black (hereafter refer to as Black) persons with HIV/AIDS (PWH) who smoke cigarettes. Participants will be randomized...
What is the current status of trial NCT07024992?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2026-06-01. Estimated completion is 2029-06-30.
What interventions are being tested in trial NCT07024992?
The interventions under investigation include: ESCAPE app + NRT (BEHAVIORAL), quiSTART app + NRT (BEHAVIORAL), Control (CTRL) (BEHAVIORAL).
Who is sponsoring clinical trial NCT07024992?
This trial is sponsored by University of Houston, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07024992's enrollment target sits among peer trials
300 167th of 2000 higher than 1,813 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI